P V Kishore, Palaian Subish, Ojha Pradip, P R Shankar
Department of Medicine, Manipal Teaching Hospital, Manipal College of Medical Sciences, Pokhara, Nepal.
Pak J Pharm Sci. 2008 Jan;21(1):51-6.
Tuberculosis is a common problem in developing countries including Nepal. Data regarding the safety profile of anti tubercular drugs is lacking in Nepal. The present study analyzed the pattern of ADRs caused by the antitubercular drugs. Inpatient files of all the TB patients who received treatment at the Manipal Teaching Hospital, Pokhara, Nepal during the period from 1st January 2001 till 31st December 2006 were taken. Altogether 326 patients were identified among which 40 (females 24, males 16) experienced at least one ADR (incidence 12.27%). The mean+/-SD age of the patients was 42.12+/-20.41 years. The most common ADR was elevated liver enzymes [24 (57.14%)] and hepatobiliary system was the most common system affected [24 (58.5%)]. More than half the ADRs [21 (52.55%)] developed with in 20 days of initiation of therapy. Isoniazid and pyrazinamide were the suspected drugs responsible for 32.32% each of the total ADRs. The mean+/-SD of the total number of drugs used in the patients were 4.77+/-1.46. The most common laboratory abnormality observed was elevated SGOT level [21 patients (52.5%)]. Seven (17.5%) patients needed specific drug treatment for managing the ADRs and 10 (25%) needed symptomatic management. Thirty five (87.5%) patients recovered following the ADR. Multiple drug therapy was the reason behind the development of 30 (75%) ADRs. It was found that 29 (72.5%) ADRs were 'probably' due to the suspected drugs. Majority [19 (47.5%)] of the ADRs were mild [level (1)]. This study shows that ADRs to anti tubercular drugs are common. Since TB is a common problem in Nepal, special efforts are needed to tackle the drug related complications associated with ATT drugs.
结核病在包括尼泊尔在内的发展中国家是一个常见问题。尼泊尔缺乏关于抗结核药物安全性的相关数据。本研究分析了抗结核药物引起的不良反应模式。选取了2001年1月1日至2006年12月31日期间在尼泊尔博卡拉马尼帕尔教学医院接受治疗的所有结核病患者的住院病历。共识别出326名患者,其中40名(女性24名,男性16名)经历了至少一种不良反应(发生率12.27%)。患者的平均年龄±标准差为42.12±20.41岁。最常见的不良反应是肝酶升高[24例(57.14%)],肝胆系统是受影响最常见的系统[24例(58.5%)]。超过一半的不良反应[21例(52.55%)]在治疗开始后20天内出现。异烟肼和吡嗪酰胺被怀疑是导致所有不良反应中各32.32%的药物。患者使用的药物总数的平均±标准差为4.77±1.46。观察到的最常见实验室异常是血清谷草转氨酶水平升高[21例患者(52.5%)]。7名(17.5%)患者需要特定药物治疗来处理不良反应,10名(25%)患者需要对症处理。35名(87.5%)患者在出现不良反应后康复。多药联合治疗是30例(75%)不良反应发生的原因。发现29例(72.5%)不良反应“可能”是由可疑药物引起的。大多数[19例(47.5%)]不良反应为轻度[1级]。本研究表明,抗结核药物的不良反应很常见。由于结核病在尼泊尔是一个常见问题,需要做出特别努力来应对与抗结核治疗药物相关的药物并发症。